<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00840515</url>
  </required_header>
  <id_info>
    <org_study_id>SMC-5467</org_study_id>
    <secondary_id>20080772</secondary_id>
    <nct_id>NCT00840515</nct_id>
  </id_info>
  <brief_title>PraevoSkin Emulsion in the Prevention of Radiation Induced Dermatitis</brief_title>
  <official_title>A Phase 2,Double Blind Randomized Study of PraevoSkin,a Melatonin Containing Emulsion, in the Prevention of Radiation Induced Dermatitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharm Olam Pharmaceuticals Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharm Olam Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2 double blind randomised study of PraevoSkin,a melatonin containing emulsion, in the
      prevention of radiation induced dermatitis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">August 2009</completion_date>
  <primary_completion_date type="Anticipated">June 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Digital Camera</measure>
    <time_frame>Weekly</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Prevention of Radiation Induced Dermatitis.</condition>
  <arm_group>
    <arm_group_label>Emulsion</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Female patientsplanned to receive whole breast radiation.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female patients at least 18 years with unilateral breast cancer following lumpectomy
             +/- chemotherapy.

          2. Planned to receive 50 Gy whole breast irradiation +/- boost to tumor bed.

          3. ECOG PERFORMANCE STATUS 0-1.

          4. Capable of giving written informed consent and following instructions for applying
             study emulsion or placebo as per control.

          5. No co-morbidities known to affect radiotherapy reactions.

          6. No co-existing acute or chronic skin disease.

          7. No evidence of infection or inflammation of breast to be treated.

          8. Not receiving chemotherapy during radiotherapy course.Biological therapy (e.g.
             Herceptin) or hormone therapy will be allowed during the study.

        Exclusion Criteria:

          1. Chemotherapy within 4 weeks prior to planned start of radiation or chemotherapy
             planned during radiation.

          2. Prior radiotherapy to any site.

          3. Collagen vascular disease.

          4. Diabetes mellitus requiring medication.

          5. Uncontrolled hypertension.

          6. Participation in other clinical study.

          7. Any contra-indicating to treatment with Melatonin.

          8. History of allergy to peanuts or fragrances.

          9. History of severe allergic reactions (e.g. asthma).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Israel</country>
  </removed_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2009</study_first_submitted>
  <study_first_submitted_qc>February 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2009</study_first_posted>
  <last_update_submitted>May 5, 2009</last_update_submitted>
  <last_update_submitted_qc>May 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Roni Eilon</name_title>
    <organization>Pharm Olam Pharmaceutics Ltd.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Radiodermatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

